X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES NATCO PHARMA VENUS REMEDIES/
NATCO PHARMA
 
P/E (TTM) x -8.2 16.0 - View Chart
P/BV x 0.1 17.2 0.7% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 VENUS REMEDIES   NATCO PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
NATCO PHARMA
Mar-14
VENUS REMEDIES/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs143877 16.3%   
Low Rs65424 15.3%   
Sales per share (Unadj.) Rs324.2223.4 145.1%  
Earnings per share (Unadj.) Rs6.431.1 20.6%  
Cash flow per share (Unadj.) Rs40.640.3 100.8%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs366.0219.5 166.7%  
Shares outstanding (eoy) m12.3433.07 37.3%   
Bonus/Rights/Conversions -PA-  
Price / Sales ratio x0.32.9 11.0%   
Avg P/E ratio x16.220.9 77.4%  
P/CF ratio (eoy) x2.616.1 15.9%  
Price / Book Value ratio x0.33.0 9.6%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m1,28221,504 6.0%   
No. of employees `0000.9NA-   
Total wages/salary Rs m2511,128 22.3%   
Avg. sales/employee Rs Th4,430.1NM-  
Avg. wages/employee Rs Th278.0NM-  
Avg. net profit/employee Rs Th87.6NM-  
INCOME DATA
Net Sales Rs m4,0007,389 54.1%  
Other income Rs m23167 13.6%   
Total revenues Rs m4,0237,556 53.2%   
Gross profit Rs m7851,793 43.8%  
Depreciation Rs m422304 138.5%   
Interest Rs m344366 93.9%   
Profit before tax Rs m421,290 3.3%   
Minority Interest Rs m046 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-37309 -12.0%   
Profit after tax Rs m791,027 7.7%  
Gross profit margin %19.624.3 80.8%  
Effective tax rate %-87.923.9 -367.2%   
Net profit margin %2.013.9 14.2%  
BALANCE SHEET DATA
Current assets Rs m2,6063,681 70.8%   
Current liabilities Rs m1,9803,123 63.4%   
Net working cap to sales %15.67.6 207.0%  
Current ratio x1.31.2 111.6%  
Inventory Days Days12889 143.4%  
Debtors Days Days4359 73.5%  
Net fixed assets Rs m5,3537,685 69.7%   
Share capital Rs m123331 37.3%   
"Free" reserves Rs m4,3936,670 65.9%   
Net worth Rs m4,5167,259 62.2%   
Long term debt Rs m1,618955 169.5%   
Total assets Rs m8,29111,957 69.3%  
Interest coverage x1.14.5 24.8%   
Debt to equity ratio x0.40.1 272.4%  
Sales to assets ratio x0.50.6 78.1%   
Return on assets %5.111.7 43.8%  
Return on equity %1.814.2 12.4%  
Return on capital %6.320.7 30.3%  
Exports to sales %039.4 0.0%   
Imports to sales %18.45.7 322.9%   
Exports (fob) Rs mNA2,908 0.0%   
Imports (cif) Rs m736421 174.8%   
Fx inflow Rs m03,445 0.0%   
Fx outflow Rs m736703 104.8%   
Net fx Rs m-7362,743 -26.8%   
CASH FLOW
From Operations Rs m9971,440 69.2%  
From Investments Rs m-461-1,089 42.4%  
From Financial Activity Rs m-571-353 161.9%  
Net Cashflow Rs m-35-1 2,355.7%  

Share Holding

Indian Promoters % 32.9 52.0 63.1%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 0.2 7.8 2.3%  
FIIs % 0.6 16.6 3.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 26.0 255.4%  
Shareholders   20,121 25,395 79.2%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   DISHMAN PHARMA  ELDER PHARMA  ALEMBIC LTD  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 14, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS